Ocular Therapeutix Reports Interim 10 Months US Based P-I Clinical Trial Results of OTX-TKI for the Treatment of Wet AMD
Shots:
- The US-based P-I trial evaluating OTX-TKI (600µg) vs aflibercept (2mg, q8w) in a ratio (3:1) in 21 patients with wet AMD, DR & other retinal diseases at 6 clinical sites in the US
- At the data cutoff of Dec 2022, OTX-TKI continues to be well tolerated with no drug-related ocular or SAEs @10mos. All OTX-TKI treated patients who were rescue-free @7mos. interim analysis remained rescue-free extending 73% rescue-free rate @~10mos., 92% reduction in treatment burden, CSFT & BCVA measurements @10mos. were comparable b/w OTX-TKI & aflibercept
- The results are being presented at the Angiogenesis, Exudation & Degeneration 2023. The company plans to meet with the US FDA to discuss future clinical trial requirements & is expected to initiate a pivotal trial in Q3’23
Ref: Globenewswire | Image: Ocular Therapeutix
Related News:- Ocular Therapeutix Reports sNDA Submission of Dextenza (dexamethasone ophthalmic insert) to the US FDA for Ocular Itching
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
